It meant that CFF‐1 could up‐regulate body's anticancer immunity via activating T cells by suppressing PD‐L1 expression of cancer cells, suggesting that CFF‐1 might be a potential immunotherapy drug in clinic for patients with prostate cancer. The gene discussed is CD274; the disease is prostate cancer.